NO982901L - Nye barbitursyrederivater, fremgangsmåter for fremstilling av slike, samt farmasöytiske midler inneholdende disse forbindelser - Google Patents

Nye barbitursyrederivater, fremgangsmåter for fremstilling av slike, samt farmasöytiske midler inneholdende disse forbindelser

Info

Publication number: NO982901L
Authority: NO; Norway
Prior art keywords: pct; group; monocycle; substituted; compounds
Prior art date: 1995-12-23

Application number

NO982901A

Other languages

English (en)

Other versions

NO982901D0 (no

NO311572B1 (no

Inventor

Elmar Bosies

Angelika Esswein

Frank Grams

Hans-Willi Krell

Ernesto Menta

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-23

Filing date

1998-06-22

Publication date

1998-08-24

1998-06-22 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1998-06-22 Publication of NO982901D0 publication Critical patent/NO982901D0/no

1998-08-24 Publication of NO982901L publication Critical patent/NO982901L/no

2001-12-10 Publication of NO311572B1 publication Critical patent/NO311572B1/no

Links

150000007656 barbituric acids Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 title 1
-1 n-octyl Chemical group 0.000 abstract 4
125000001424 substituent group Chemical group 0.000 abstract 3
229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
125000004193 piperazinyl group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
235000010290 biphenyl Nutrition 0.000 abstract 1
239000004305 biphenyl Substances 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
125000005936 piperidyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/66—Thiobarbituric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO19982901A 1995-12-23 1998-06-22 Nye barbitursyrederivater, farmasöytiske midler inneholdende slike forbindelser, samt anvendelse av slike forbindelser tilfremstilling av et farmasöytisk middel NO311572B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19548624A DE19548624A1 (de)	1995-12-23	1995-12-23	Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PCT/EP1996/005766 WO1997023465A1 (en)	1995-12-23	1996-12-20	New barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds

Publications (3)

Publication Number	Publication Date
NO982901D0 NO982901D0 (no)	1998-06-22
NO982901L true NO982901L (no)	1998-08-24
NO311572B1 NO311572B1 (no)	2001-12-10

Family

ID=7781338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982901A NO311572B1 (no)	1995-12-23	1998-06-22	Nye barbitursyrederivater, farmasöytiske midler inneholdende slike forbindelser, samt anvendelse av slike forbindelser tilfremstilling av et farmasöytisk middel

Country Status (22)

Country	Link
US (2)	US6110924A (no)
EP (1)	EP0869947B1 (no)
JP (1)	JP4198752B2 (no)
KR (1)	KR100440035B1 (no)
CN (1)	CN1318406C (no)
AT (1)	ATE226575T1 (no)
BR (1)	BR9612232A (no)
CZ (1)	CZ292503B6 (no)
DE (2)	DE19548624A1 (no)
DK (1)	DK0869947T3 (no)
ES (1)	ES2184903T3 (no)
HU (1)	HUP9901065A3 (no)
IL (1)	IL125048A (no)
MX (1)	MX9805063A (no)
NO (1)	NO311572B1 (no)
NZ (1)	NZ325802A (no)
PL (1)	PL190217B1 (no)
PT (1)	PT869947E (no)
RU (1)	RU2177475C2 (no)
TW (1)	TW518324B (no)
WO (1)	WO1997023465A1 (no)
ZA (1)	ZA9610765B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU746853B2 (en)	1997-06-21	2002-05-02	Roche Diagnostics Gmbh	Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de)	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
RU2188196C2 (ru) *	1998-05-26	2002-08-27	Ашкинази Римма Ильинична	N-замещенные производные 5-оксииминобарбитуровой кислоты
US6350786B1 (en)	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
US6265578B1 (en)	1999-02-12	2001-07-24	Hoffmann-La Roche Inc.	Pyrimidine-2,4,6-triones
AR033651A1 (es) *	1999-10-01	2004-01-07	Hoffmann La Roche	Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
IL154946A0 (en)	2000-10-26	2003-10-31	Pfizer Prod Inc	Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US6716845B2 (en) *	2001-03-30	2004-04-06	Hoffmann-La Roche Inc.	Barbituric acid derivatives
ES2274043T3 (es) *	2001-05-03	2007-05-16	F. Hoffmann-La Roche Ag	Combinacion de un inhibidor de gelatina con un agente antitumoral y usos de la misma.
MXPA03009995A (es) *	2001-05-09	2004-06-30	Univ Michigan	Uso de composiciones para tratar rosacea.
AU2002346729A1 (en) *	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
NI200300045A (es) *	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
WO2004084903A1 (en) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment of chronic wounds
WO2004110457A1 (en) *	2003-06-06	2004-12-23	F. Hoffmann-La Roche Ag	Matrix metalloproteinases inhibitors for the stimulation and protection of bone marrow stem cells
EP1737464B1 (en) *	2004-04-01	2008-07-23	F. Hoffmann-La Roche AG	Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
AU2005230380B2 (en) *	2004-04-01	2010-09-23	Universite De Liege	Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones
EP1632489A1 (en) *	2004-08-24	2006-03-08	University of Liege	5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use.
RU2412189C1 (ru) *	2009-07-14	2011-02-20	Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ)	СПОСОБ ПОЛУЧЕНИЯ 5-(4-ОКСО-2-ТИОКСО-1,3,4,5-ТЕТРАГИДРО-2Н-ХРОМЕНО[2,3-d]ПИРИМИДИН-5-ИЛ)-2-ТИОКСОДИГИДРОПИРИМИДИН-4,6(1Н,5Н)-ДИОНА
CN102234249B (zh) *	2010-04-23	2013-08-28	首都医科大学	N-(六氢嘧啶-1,3-二基)-二-l-氨基酸甲酯及其制备方法和应用
WO2011153359A1 (en)	2010-06-04	2011-12-08	Albany Molecular Research, Inc.	Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101822417B1 (ko) *	2017-06-14	2018-01-29	주식회사 청도제약	인간의 체액에서 산화 스트레스를 측정하기 위한 방법
KR102432016B1 (ko)	2020-07-31	2022-08-16	부산대학교 산학협력단	신경염증질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2078323A (en) *		1937-04-27		C-amino-substituted barbituric
US2084136A (en) *	1933-06-03	1937-06-15	Heyden Chem Fab	Barbituric acid containing in the 5-position a pyridine group and method of preparing the same
DE763145C (de) *	1942-05-29	1954-05-03	Chem Fab Von Heyden A G	Verfahren zur Herstellung von 5-AEthyl-5-piperidinobarbitursaeure
US3930006A (en) *	1963-04-30	1975-12-30	Aspro Nicholas Ltd	Antiparkinsonism compositions and method
DE1246743B (de) *	1965-01-12	1967-08-10	Dresden Arzneimittel	Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
DE19726427A1 (de) *	1997-06-23	1998-12-24	Boehringer Mannheim Gmbh	Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

1995
- 1995-12-23 DE DE19548624A patent/DE19548624A1/de not_active Withdrawn
1996
- 1996-12-20 JP JP52331897A patent/JP4198752B2/ja not_active Expired - Fee Related
- 1996-12-20 BR BR9612232A patent/BR9612232A/pt not_active IP Right Cessation
- 1996-12-20 WO PCT/EP1996/005766 patent/WO1997023465A1/en not_active Ceased
- 1996-12-20 ZA ZA9610765A patent/ZA9610765B/xx unknown
- 1996-12-20 RU RU98113916/04A patent/RU2177475C2/ru not_active IP Right Cessation
- 1996-12-20 CN CNB961800275A patent/CN1318406C/zh not_active Expired - Fee Related
- 1996-12-20 US US09/091,352 patent/US6110924A/en not_active Expired - Fee Related
- 1996-12-20 NZ NZ325802A patent/NZ325802A/xx unknown
- 1996-12-20 HU HU9901065A patent/HUP9901065A3/hu unknown
- 1996-12-20 CZ CZ19981968A patent/CZ292503B6/cs not_active IP Right Cessation
- 1996-12-20 EP EP96944612A patent/EP0869947B1/en not_active Expired - Lifetime
- 1996-12-20 AT AT96944612T patent/ATE226575T1/de not_active IP Right Cessation
- 1996-12-20 DE DE69624500T patent/DE69624500T2/de not_active Expired - Fee Related
- 1996-12-20 IL IL12504896A patent/IL125048A/en not_active IP Right Cessation
- 1996-12-20 DK DK96944612T patent/DK0869947T3/da active
- 1996-12-20 PT PT96944612T patent/PT869947E/pt unknown
- 1996-12-20 KR KR10-1998-0704855A patent/KR100440035B1/ko not_active Expired - Fee Related
- 1996-12-20 ES ES96944612T patent/ES2184903T3/es not_active Expired - Lifetime
- 1996-12-20 PL PL96327466A patent/PL190217B1/pl not_active IP Right Cessation
1997
- 1997-01-28 TW TW086101091A patent/TW518324B/zh not_active IP Right Cessation
1998
- 1998-06-22 NO NO19982901A patent/NO311572B1/no unknown
- 1998-06-22 MX MX9805063A patent/MX9805063A/es not_active IP Right Cessation
2000
- 2000-06-16 US US09/594,700 patent/US6472396B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL125048A0 (en)	1999-01-26
NZ325802A (en)	2000-05-26
HUP9901065A3 (en)	2001-10-29
BR9612232A (pt)	1999-07-13
ATE226575T1 (de)	2002-11-15
WO1997023465A1 (en)	1997-07-03
TW518324B (en)	2003-01-21
KR19990076734A (ko)	1999-10-15
DK0869947T3 (da)	2003-02-24
CN1318406C (zh)	2007-05-30
EP0869947B1 (en)	2002-10-23
ZA9610765B (en)	1998-07-17
JP2000505069A (ja)	2000-04-25
CN1209123A (zh)	1999-02-24
EP0869947A1 (en)	1998-10-14
PL190217B1 (pl)	2005-11-30
CZ196898A3 (cs)	1998-09-16
HUP9901065A2 (hu)	1999-09-28
NO982901D0 (no)	1998-06-22
IL125048A (en)	2004-02-19
AU1303697A (en)	1997-07-17
PT869947E (pt)	2003-03-31
DE69624500T2 (de)	2003-07-17
NO311572B1 (no)	2001-12-10
RU2177475C2 (ru)	2001-12-27
JP4198752B2 (ja)	2008-12-17
US6472396B1 (en)	2002-10-29
KR100440035B1 (ko)	2004-09-18
DE69624500D1 (de)	2002-11-28
DE19548624A1 (de)	1997-06-26
PL327466A1 (en)	1998-12-07
US6110924A (en)	2000-08-29
AU722513B2 (en)	2000-08-03
MX9805063A (es)	1998-10-31
ES2184903T3 (es)	2003-04-16
CZ292503B6 (cs)	2003-10-15

Publication	Publication Date	Title
NO982901L (no)	1998-08-24	Nye barbitursyrederivater, fremgangsmåter for fremstilling av slike, samt farmasöytiske midler inneholdende disse forbindelser
ES8101586A1 (es)	1980-12-16	Un procedimiento para la preparacion de nuevos derivados de quinazolina.
BG104254A (en)	2001-08-31	Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
KR970706813A (ko)	1997-12-01	단백질 키나아제의 억제물질로서 유용한 제약용 피라졸 조성물(pharmaceutical pyrazole compositions useful as inhibitors of protein kinases)
WO1991013055A3 (en)	1991-10-31	New aryl- and heteroarylethenylene derivatives and process for their preparation
TR199800924T2 (xx)	1998-08-21	Quinoline t�revleri.
GEP20033028B (en)	2003-07-25	Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
DK0677046T3 (da)	1997-09-01	Piperazinderivater som 5-HT-antagonister.
DE50011034D1 (de)	2005-09-29	N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PT920426E (pt)	2004-02-27	Novos derivados de tiazole com efeito inibidor de fosfodiesterase
MXPA02011352A (es)	2005-07-01	Nuevos derivados de benzofurano.
MX9400253A (es)	1994-08-31	Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
ATE282615T1 (de)	2004-12-15	Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel
DK0706517T3 (da)	1999-06-28	Pyridazinonderivater med farmaceutisk virkning
FR2798126B1 (fr)	2001-10-19	Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE234818T1 (de)	2003-04-15	Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AR027035A1 (es)	2003-03-12	Pirroles sustituidos
TW333525B (en)	1998-06-11	New perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them the invention relates to perhydroisoindole derivatives of general formula (I), and their salts when they exist advantageously as neurokinin A antagonists.
NO981655L (no)	1998-06-11	Fenantridin-derivater, fremgangsmÕter for fremstilling derav og medikamenter inneholdende fenantridin-derivater
TW350843B (en)	1999-01-21	2-(4-pyrazolyloxy-pyrimidin-5-yl) acetic acid derivatives